{"id":2785,"date":"2025-02-03T15:39:17","date_gmt":"2025-02-03T12:39:17","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2785"},"modified":"2025-03-07T13:17:20","modified_gmt":"2025-03-07T10:17:20","slug":"entrada-therapeutics-receives-uk-authorization-to-begin-elevate-44-201","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/es\/entrada-therapeutics-receives-uk-authorization-to-begin-elevate-44-201\/","title":{"rendered":"Entrada Therapeutics recibe autorizaci\u00f3n del Reino Unido para iniciar el tratamiento con ELEVATE-44-201"},"content":{"rendered":"<p class=\"wp-block-paragraph\">El estudio cl\u00ednico de fase 1\/2 de dosis m\u00faltiples ascendentes (MAD) de ENTR-601-44, ELEVATE-44-201, fue autorizado por la Agencia Reguladora de Medicamentos y Productos Sanitarios (MHRA) y el Comit\u00e9 de \u00c9tica de Investigaci\u00f3n para el Ensayo Cl\u00ednico de un Producto Medicinal en Investigaci\u00f3n del Reino Unido. El estudio tiene como objetivo tratar la distrofia muscular de Duchenne (DMD) en pacientes que tienen una mutaci\u00f3n confirmada en el gen DMD que es susceptible de omisi\u00f3n del ex\u00f3n 44.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">\u00bfQu\u00e9 es el estudio cl\u00ednico ELEVATE-44-201?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">ELEVATE-44-201 es un estudio global, de dos partes, aleatorizado, doble ciego y controlado con placebo de fase 1\/2 que eval\u00faa la seguridad, tolerabilidad y eficacia de ENTR-601-44 en pacientes ambulatorios con DMD que son susceptibles de omisi\u00f3n del ex\u00f3n 44.<\/p>","protected":false},"excerpt":{"rendered":"<p>ELEVATE-44-201, a Phase 1\/2 multiple ascending dose (MAD) clinical study of ENTR-601-44, was authorized by the UK&#8217;s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for the Clinical Trial of an Investigational Medicinal Product. The study aims to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2788,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[235,49,233,234,141,127,77,48],"class_list":["post-2785","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevate-44-201","tag-england","tag-entrada","tag-entrada-therapeutics","tag-exon-44","tag-exon-44-skipping","tag-exon-skipping","tag-uk"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/2785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/comments?post=2785"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/posts\/2785\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media\/2788"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/media?parent=2785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/categories?post=2785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/es\/wp-json\/wp\/v2\/tags?post=2785"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}